Skip to main content

Market Overview

Aeterna Zentaris Starts Animal Studies For Macimorelin For Amyotrophic Lateral Sclerosis

Share:
Aeterna Zentaris Starts Animal Studies For Macimorelin For Amyotrophic Lateral Sclerosis
  • Aeterna Zentaris Inc (NASDAQ: AEZS) has commenced the previously announced preclinical program to qualify macimorelin for clinical development as a potential treatment option for amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease).
  • The preclinical development program is part of the recently executed Material Transfer Agreement (MTA) with The University of Queensland.
  • The University researchers will conduct preclinical studies in disease-related in-vitro and in-vivo models to demonstrate the therapeutic potential of macimorelin on disease progression and ALS-specific pathology.
  • In the event of positive preclinical results, the Company has the exclusive right to acquire a license from The University on the therapeutic use of macimorelin to treat ALS.
  • Aeterna Zentaris' lead product, macimorelin, is the only FDA-approved oral drug indicated for diagnosing adult growth hormone deficiency (AGHD) and is currently marketed in the U.S. under the tradename Macrilen by Novo Nordisk A/S (NYSE: NVO).
  • Price Action: AEZS shares are trading 1.79% lower at $0.85 on the last check Monday.
 

Related Articles (AEZS)

View Comments and Join the Discussion!

Posted-In: Briefs multiple sclerosisBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com